secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-02-18T23:59:59+00:00
Accession:  0001493152-25-007080
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir-1 reduces oxidative stress in human retinal cells, advancing potential AMD treatment
--------------------------------------------------------------------------------

- Telomir-1 significantly reduced reactive oxygen species (ROS) elevation from copper and iron exposure in human retinal cell lines.
- Compound showed strong ROS regulation at low concentrations, suggesting a regulatory effect beyond metal chelation.
- Study targets age-related macular degeneration (AMD) and other retinal diseases linked to oxidative stress.
- Company initiating AMD disease models to evaluate in vivo efficacy and support potential clinical development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225007080/0001493152-25-007080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225007080/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-007080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer